Chugai partners with Osaka University in £62 million immunology collaboration
Chugai Pharmaceuticals (TOKYO: 4519) has announced a collaboration agreement with Osaka University in advanced immunology research worth up to £62 million.
The partnership will combine the expertise in immunology, live imaging and bioinformatics of the Osaka University Immunology Frontier Center and Chugai’s aim of utilising middle molecule technologies to focus on the research and development of first-in-class pharmaceuticals. Through the collaboration, the pair hopes to eradicate the obstacles between basic research and clinical application research.
Chugai will provide one billion yen a year for 10 years in return for access to information on the results of independent basic research projects and the right of first refusal for joint research. In addition, a collaboration promotion laboratory will be set up at the university to implement joined-up research towards clinical application.
The overall aim is to have five to 10 joint research projects in progress on a constant basis.
Osamu Nagayma, chairman and CEO at Chugai, says: “Chugai has innovative proprietary technologies for antibody engineering and middle molecules, which enables drug discovery of targets that could not be done previously. Through the combination of these technologies and the diverse research results achieved through the global top-class immunology research at IFReC, we are confident of providing multiple innovative pharmaceuticals to patients.”
Autifony Therapeutics has announced that it has entered an exclusive global licensing agreement with Jazz …
Halozyme Therapeutics has announced a global collaboration and non-exclusive license with Acumen Pharmaceuticals, providing Acumen …